NVS up +1.65% percent Today $NVS High is at 94.24
Post# of 54
Posted On: 11/13/2014 11:35:05 AM
NVS up +1.65% percent Today $NVS High is at 94.24 and the Low 93.65 with current volume of 238,147.
Recent News posted below.
Novartis Ag NVS other info.
http://investorshangout.com/Novartis-Ag-NVS-52134/
NVS Novartis Ag Recent Headline News
Tracking Tweedy Browne Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - 20 mins ago
MMM: 158.48 (+0.80), KOF: 101.09 (-1.39), LMT: 188.32 (+1.45), DNOW: 28.15 (-0.67), WMT: 82.04 (+2.84), CNQ: 36.65 (-0.36), GOOG: 545.89 (-1.42), DEO: 118.79 (+0.93), BSBR: 5.51 (-0.05), NOV: 71.42 (-1.58), JNJ: 109.04 (+0.29), GOOGL: 556.53 (-1.72), BK: 39.34 (-0.40), UNP: 121.08 (+0.37), CSCO: 25.68 (+0.57), MA: 83.95 (-0.40), JOY: 53.01 (-0.74), TMK: 53.32 (+0.06), PSX: 71.54 (-1.50), DVN: 63.13 (-0.94), AXP: 91.46 (-0.09), UN: 39.34 (+0.48), EMR: 63.78 (-0.27), HAL: 51.61 (-1.62), COP: 70.45 (-0.75), WFC: 53.37 (-0.17), UL: 40.85 (+0.45), ITW: 93.15 (-0.08), PM: 88.12 (+0.22), TOT: 56.66 (-0.51), BAX: 72.18 (+0.85), ANAT: 114.64 (-0.41), BRK.B: 146.14 (+0.62), VZ: 51.08 (+0.26), CMCSA: 54.36 (+0.76), BRK.A: 219,139.18 (+1,038.18), NVS: 94.51 (+1.85)
Critical Alerts For American Eagle Outfitters, Novartis, VIVUS, King Digital and Canadian Solar Released By InvestorsObserver
PR Newswire - 2 hrs 3 mins ago
InvestorsObserver issues critical PriceWatch Alerts for AEO, NVS, VVUS, KING and CSIQ.
AEO: 13.62 (-0.18), VVUS: 3.35 (+0.01), CSIQ: 26.26 (-1.82), KING: 15.24 (+1.21), NVS: 94.51 (+1.85)
Hematopoietic Stem Cell Transplantation Therapeutic Market Pipeline Overview, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 10:30PM CST
The report "Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/hematopoieti...eport.html .
ATNM: 6.19 (-0.04), CLDX: 14.60 (-0.21), ATHX: 1.36 (-0.07), NVS: 94.51 (+1.85)
Ad Comm meeting approaches for Alcon intraocular lens
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 12:13PM CST
NVS: 94.51 (+1.85)
GenVec Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 12, 6:55AM CST
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and nine-month periods ended September 30, 2014. For the three-month period ended September 30, 2014, the company reported a net loss of $1.6 million or $0.10 per share on revenues of $0.3 million as compared to a net loss of $3.0 million or $0.23 per share on revenues of $1.6 million in the same period in the prior year. For the nine-month period ended September 30, 2014, the company reported a net loss of $4.2 million or $0.27 per share on revenues of $2.5 million as compared to a net loss of $9.1 million or $0.71 per share on revenues of $3.5 million in the same period in the prior year. GenVec ended the third quarter of 2014 with $12.8 million in cash, cash equivalents, and short-term investments.
GNVC: 1.98 (unch), NVS: 94.51 (+1.85)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 77.77 (-0.04), SJR: 26.31 (+0.11), PRGO: 155.46 (+0.59), XYL: 37.44 (-0.11), CHRW: 72.90 (+0.04), MDLZ: 37.93 (+0.01), MKC: 73.39 (+0.16), MDU: 25.23 (-0.19), SYY: 38.80 (-0.14), PDCO: 45.67 (+0.54), PNR: 68.53 (+0.09), TRI: 38.15 (-0.09), UPS: 108.41 (-0.21), PEP: 98.47 (+1.31), AGN: 197.27 (+0.76), MSI: 64.44 (+0.74), NOV: 71.42 (-1.58), NWN: 47.08 (-0.01), EGN: 66.80 (-1.90), EBAY: 54.40 (+0.34), QCOM: 70.57 (+0.28), AMAT: 22.76 (+0.27), ACN: 84.31 (+0.19), AAPL: 112.93 (+1.68), MA: 83.95 (-0.40), SCHW: 28.72 (-0.06), STR: 23.90 (-0.04), SE: 38.29 (-0.67), GAS: 51.89 (-0.23), IRM: 38.07 (+0.02), WM: 49.40 (+0.02), CMP: 89.12 (+0.43), VRSK: 62.78 (-0.34), GILD: 103.93 (-2.97), EXPD: 43.84 (-0.07), TFX: 114.61 (+0.14), CVS: 89.66 (+0.37), PG: 89.41 (-0.07), PX: 126.40 (+0.17), NVS: 94.51 (+1.85)
Malaria No More Reaches Power Of One Campaign Goal for Treatments In Zambia
PR Newswire - Wed Nov 12, 5:54AM CST
Malaria No More announced today that funding has been secured and an order has been placed for three million life-saving malaria treatments in advance of its three year, end of 2015 goal. The Power of One (Po1) campaign uses the latest social, mobile and e-commerce technologies to rally the global public in the fight against malaria. This is a major milestone for the organization and Po1 campaign partners Novartis (NYSE: NVS), the world's leading provider of malaria treatments; and Alere Inc. (NYSE: ALR), the world's leading provider of rapid diagnostic tests for infectious diseases, including malaria. To date, one million rapid diagnostic tests have been sent to Zambia through Po1.
ALR: 39.92 (-0.18), NVS: 94.51 (+1.85)
Global Grass Pollen Allergy Clinical Trials Review, H2 2014: Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/sjpbh2/grass_pollen) has announced the addition of the "Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Grass Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Grass Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Grass Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Grass Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Laboratorios LETI S.L. - Circassia Holdings Ltd. - Merck KGaA - Merck & Co., Inc. - BioTech Tools s.a. - Novartis AG - Biomay AG Clinical Trial Overview of Top Institutes / Government - University of Zurich - Imperial College London - Johann Wolfgang Goethe University Hospitals - Medical University of Vienna - Charite - Universitatsmedizin Berlin - Azienda Ospedaliera L. Sacco - Nationwide Children's Hospital - Bispebjerg Hospital - University Hospital Freiburg - Rush University Medical Center For more information visit http://www.researchandmarkets.com/research/sj...ass_pollen
MRK: 59.69 (+0.38), NVS: 94.51 (+1.85)
Novartis and Malaria No More help fulfill malaria treatment goal in Zambia by raising funds for three million treatments through Power of One
M2 - Wed Nov 12, 3:18AM CST
o Power of One campaign, supported by exclusive treatment sponsor Novartis, raises funds for three million treatments for children with malaria
NVS: 94.51 (+1.85)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.70 (+0.16), JNJ: 109.04 (+0.29), IDRA: 2.53 (-0.03), DERM: 15.99 (-0.26), MRK: 59.69 (+0.38), PFE: 30.54 (+0.12), AZN: 74.68 (+0.42), AMGN: 160.52 (-1.41), GSK: 45.87 (+0.25), HSP: 57.91 (-0.18), NVS: 94.51 (+1.85), CELG: 107.53 (-0.72)
Product and Pipeline Analysis of the Global Vaccines Market
M2 - Tue Nov 11, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/4nt5s9/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Vaccines Market " report to their offering. Vaccines represent a class of biologics that are administered to prevent infectious diseases to reduce mortality and morbidity. It is estimated that the introduction of vaccines has reduced the incidence of various diseases by greater than 90%. This study examines the global vaccines market, including marketed products and products under clinical development. It also presents an overview of the value chain and regulatory environment, and offers profiles of key marketed and pipeline products. The market is segmented into infectious disease vaccines, cancer vaccines, allergy vaccines, and others (e.g., vaccines for physiological disorders such as diabetes and Alzheimer's disease). The base year is 2013. Key Findings:Vaccines are a class of biologics administered to prevent infectious diseases and reduce mortality and morbidity. - Vaccines are now available for prevention of about infectious diseases. - Coupled with powerful techniques such as polymerase chain reaction (PCR), mass spectrometry, and next-generation sequencing, the vaccine industry experienced a paradigm shift resulting in innovation and engineering of novel vaccines such as dendritic cell, DNA, and synthetic. - Infectious disease vaccines-particularly viral vaccines-represent the largest share in terms of products under clinical trial. There is an increased focus on developing vaccines with alternative delivery routes, such as oral and intranasal, to effectively replace the conventional injection method of administration. - One of the hallmarks of vaccine development is the improved understanding of the immune system. As a result, developers are pursuing vaccines for physiological diseases. - Developers also are researching vaccines for emerging infectious diseases such as respiratory syncytial virus (RSV), norovirus, human immunodeficiency virus (HIV), Epstein-Barr, malaria, and Leishmaniasis. - The United States, Europe, and Japan represent the largest markets for vaccine manufacturers; however, with increasing healthcare spending and awareness, emerging regions represent the fastest-growing and attractive markets. Key Topics Covered: 1. Executive Summary 2. Methodology and Scope 3. Introduction 4. Global Regulatory Oversight 5. Competitive Landscape 6. Competitive Landscape-Bacterial Vaccines 7. Competitive Landscape-Viral Vaccines 8. Competitive Landscape-Parasitic Vaccines 9. Competitive Landscape-Cancer Vaccines 10. Competitive Landscape-Allergy Vaccines 11. Competitive Landscape-Other Vaccines 12. Bacterial Vaccine Product Dashboard 13. Viral Vaccine Product Dashboard 14. Parasitic Vaccine Product Dashboard 15. Cancer Vaccine Product Dashboard 16. Allergy Vaccine Product Dashboard 17. Other Vaccine Products Dashboard 18. Timeline of Key Events 19. Conclusions Companies Mentioned - AFFiRiS - Archivel Farma - Biondvax - Bionor Pharma - Dendreon - GSK - Greer Laboratories - Immunitor - Inovio - Merck & Co - Nabi - Northwest Biotherapeutics - Novartis - PaxVax - Pfizer - Sanofi - Vaccinogen For more information visit http://www.researchandmarkets.com/research/4n...roduct_and
NWBO: 6.01 (+0.13), MRK: 59.69 (+0.38), NVS: 94.51 (+1.85)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 114.34 (-2.34), GILD: 103.90 (-3.00), MRK: 59.69 (+0.38), DNDN: 0.15 (-0.01), AZN: 74.68 (+0.42), TEVA: 57.80 (-0.64), ABBV: 64.05 (+0.29), GSK: 45.87 (+0.25), BMY: 57.98 (-0.63), NVS: 94.51 (+1.85)
Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk
PR Newswire - Tue Nov 11, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Impax Laboratories Inc. (NASDAQ: IPXL), and Novo Nordisk A/S (NYSE: NVO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 10, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,613.74, up 0.23% and the NASDAQ Composite closed at 4,651.62, up 0.41%. The S&P 500 finished the session 0.31% higher at 2,038.26. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.00, up 1.00%, with the index gaining 11.86% in the previous three months. Register for your complimentary reports on these five stocks at:
IPXL: 29.41 (+0.02), NVO: 44.08 (-0.24), AZN: 74.68 (+0.42), SLXP: 96.40 (+0.85), NVS: 94.51 (+1.85)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.69 (+0.38), AZN: 74.68 (+0.42), AMGN: 160.52 (-1.41), TEVA: 57.80 (-0.64), THRX: 13.33 (+0.01), GSK: 45.87 (+0.25), SNY: 46.78 (+0.22), REGN: 397.52 (-3.59), NVS: 94.51 (+1.85)
Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lcrf6q/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Plexxikon Inc. - Novartis AG - Exelixis, Inc. - Deciphera Pharmaceuticals, LLC Drug Profiles - vandetanib - everolimus - cabozantinib s-malate - dabrafenib mesylate - rebastinib tosylate - PLX-7486 - CLM-3 - CLM-29 For more information visit http://www.researchandmarkets.com/research/lc...ry_thyroid
AZN: 74.68 (+0.42), GSK: 45.87 (+0.25), NVS: 94.51 (+1.85), EXEL: 1.81 (unch)
WomenHeart Launches First National Patient Education Campaign For Heart Failure In Women
PR Newswire - Mon Nov 10, 4:41PM CST
WomenHeart: The National Coalition for Women with Heart Disease announces the launch of the first national patient education campaign to raise awareness about women and heart failure. Heart failure is the leading cause of hospitalizations in women over the age of 65, and women account for 50 percent of all heart failure-related hospital admissions²; yet, only 25 percent of women are involved in heart failure studies³. The new campaign, which is supported by grants from St. Jude Medical Foundation and Novartis Pharmaceuticals Corporation, and sponsored by Amgen, aims to raise public awareness about women and heart failure, educate and support women with or at risk for heart failure, and develop recommendations for gender-specific heart failure research.
STJ: 65.90 (+0.22), NVS: 94.51 (+1.85)
UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:30PM CST
UCB SA (UCBJF) entered into an agreement with Advent International and Avista Capital Partners for the sale of its specialty generics subsidiary for $1.525 billion.
LCI: 49.67 (-0.06), LLY: 67.94 (+0.54), GSK: 45.87 (+0.25), NVS: 94.51 (+1.85)
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - Mon Nov 10, 1:03PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).
TRX.VN: 0.550 (-0.020), NVS: 94.51 (+1.85)
Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020
M2 - Mon Nov 10, 10:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5npxt/nonhodgkin) has announced the addition of the "Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020" report to their offering. The approval of Rituxan (rituximab) has caused the size of the Non-Hodgkin Lymphoma (NHL) market to increase dramatically over the last two decades. This growth is expected to continue at a moderate pace during the forecast period, from $5.6 billion in 2013 culminating in revenues of $9.2 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.4%, in the major developed markets. In 2013, the major share of the global NHL market was attributed to by the US, representing 53% of the overall NHL market and this dominance is expected to be retained throughout the forecast period. The increasing uptake of new targeted therapies, especially novel small molecule inhibitors in the relapsed and refractory setting, along with the dominant usage of Rituxan is expected to fuel market growth in all the major developed markets. The expected launches of premium-priced novel antibodies and small molecule inhibitors, especially protein kinase inhibitors, targeting both indolent and aggressive sub-types of NHLs will widen the treatment population eligible for novel targeted and immunotherapies. The anticipated approval of promising pipeline drug candidates, Roche's obinutuzumab, Novartis' Afinitor (everolimus), Takeda's alisertib and Biovest's BiovaxID (dasiprotimut T) and GlaxoSmithKline's Arzerra (ofatumumab) for various NHL subtypes is a key driver for the steady increase in NHL market size. Despite of a flurry of expected launches, the growth in market is not anticipated to grow rapidly, particularly due to loss of patent exclusivity of Rituxan during the forecast period. Recently Launched Targeted and Immunotherapies has Widened Treatment Alternatives for Specific Sub-types Over the past two decades, significant progress has been made in the development of new therapies for NHL. Perhaps the most important milestone is the addition of Rituxan, approved by the US Food and Drug Administration (FDA) for relapsed or refractory Cluster of Differentiation (CD) 20-positive B-cell lymphoma in 1997. Following the approval of Rituxan in 1997, the US FDA approved five other monoclonal Antibodies (mAbs): Campath (alemtuzumab) in 2001, Bexxar (tositumomab) in 2003, Zevalin (ibritumomab tiuxetan) in 2002, Arzerra in 2009, and Adcetris (brentuximab vedotin) in 2011. Another novel mAb, mogamulizumab, which is still in Phase III clinical trials in the US, has already gained approval in Japan. The majority of these drugs are approved for the treatment of specific NHL sub-types. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Pipeline Products 5 Market Forecast to 2020 6 Deals and Strategic Consolidations 7 Appendix For more information visit http://www.researchandmarkets.com/research/r5npxt/nonhodgkin
NVS: 94.51 (+1.85)
Recent News posted below.
Novartis Ag NVS other info.
http://investorshangout.com/Novartis-Ag-NVS-52134/
NVS Novartis Ag Recent Headline News
Tracking Tweedy Browne Portfolio - Q3 2014 Update
John Vincent - at Seeking Alpha - 20 mins ago
MMM: 158.48 (+0.80), KOF: 101.09 (-1.39), LMT: 188.32 (+1.45), DNOW: 28.15 (-0.67), WMT: 82.04 (+2.84), CNQ: 36.65 (-0.36), GOOG: 545.89 (-1.42), DEO: 118.79 (+0.93), BSBR: 5.51 (-0.05), NOV: 71.42 (-1.58), JNJ: 109.04 (+0.29), GOOGL: 556.53 (-1.72), BK: 39.34 (-0.40), UNP: 121.08 (+0.37), CSCO: 25.68 (+0.57), MA: 83.95 (-0.40), JOY: 53.01 (-0.74), TMK: 53.32 (+0.06), PSX: 71.54 (-1.50), DVN: 63.13 (-0.94), AXP: 91.46 (-0.09), UN: 39.34 (+0.48), EMR: 63.78 (-0.27), HAL: 51.61 (-1.62), COP: 70.45 (-0.75), WFC: 53.37 (-0.17), UL: 40.85 (+0.45), ITW: 93.15 (-0.08), PM: 88.12 (+0.22), TOT: 56.66 (-0.51), BAX: 72.18 (+0.85), ANAT: 114.64 (-0.41), BRK.B: 146.14 (+0.62), VZ: 51.08 (+0.26), CMCSA: 54.36 (+0.76), BRK.A: 219,139.18 (+1,038.18), NVS: 94.51 (+1.85)
Critical Alerts For American Eagle Outfitters, Novartis, VIVUS, King Digital and Canadian Solar Released By InvestorsObserver
PR Newswire - 2 hrs 3 mins ago
InvestorsObserver issues critical PriceWatch Alerts for AEO, NVS, VVUS, KING and CSIQ.
AEO: 13.62 (-0.18), VVUS: 3.35 (+0.01), CSIQ: 26.26 (-1.82), KING: 15.24 (+1.21), NVS: 94.51 (+1.85)
Hematopoietic Stem Cell Transplantation Therapeutic Market Pipeline Overview, Key Players & Drugs Profiles H2 2014
PRWeb - Wed Nov 12, 10:30PM CST
The report "Hematopoietic Stem Cell Transplantation - Pipeline Review, H2 2014" provides comprehensive information on the therapeutic development for Hematopoietic Stem Cell Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hematopoietic Stem Cell Transplantation and special features on late-stage and discontinued projects. Complete Report is Available @ http://www.rnrmarketresearch.com/hematopoieti...eport.html .
ATNM: 6.19 (-0.04), CLDX: 14.60 (-0.21), ATHX: 1.36 (-0.07), NVS: 94.51 (+1.85)
Ad Comm meeting approaches for Alcon intraocular lens
Seeking Alpha - at Seeking Alpha - Wed Nov 12, 12:13PM CST
NVS: 94.51 (+1.85)
GenVec Reports Third Quarter 2014 Financial Results
PR Newswire - Wed Nov 12, 6:55AM CST
GenVec, Inc. (NASDAQ: GNVC) today reported financial results for the three-month and nine-month periods ended September 30, 2014. For the three-month period ended September 30, 2014, the company reported a net loss of $1.6 million or $0.10 per share on revenues of $0.3 million as compared to a net loss of $3.0 million or $0.23 per share on revenues of $1.6 million in the same period in the prior year. For the nine-month period ended September 30, 2014, the company reported a net loss of $4.2 million or $0.27 per share on revenues of $2.5 million as compared to a net loss of $9.1 million or $0.71 per share on revenues of $3.5 million in the same period in the prior year. GenVec ended the third quarter of 2014 with $12.8 million in cash, cash equivalents, and short-term investments.
GNVC: 1.98 (unch), NVS: 94.51 (+1.85)
Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST
WDFC: 77.77 (-0.04), SJR: 26.31 (+0.11), PRGO: 155.46 (+0.59), XYL: 37.44 (-0.11), CHRW: 72.90 (+0.04), MDLZ: 37.93 (+0.01), MKC: 73.39 (+0.16), MDU: 25.23 (-0.19), SYY: 38.80 (-0.14), PDCO: 45.67 (+0.54), PNR: 68.53 (+0.09), TRI: 38.15 (-0.09), UPS: 108.41 (-0.21), PEP: 98.47 (+1.31), AGN: 197.27 (+0.76), MSI: 64.44 (+0.74), NOV: 71.42 (-1.58), NWN: 47.08 (-0.01), EGN: 66.80 (-1.90), EBAY: 54.40 (+0.34), QCOM: 70.57 (+0.28), AMAT: 22.76 (+0.27), ACN: 84.31 (+0.19), AAPL: 112.93 (+1.68), MA: 83.95 (-0.40), SCHW: 28.72 (-0.06), STR: 23.90 (-0.04), SE: 38.29 (-0.67), GAS: 51.89 (-0.23), IRM: 38.07 (+0.02), WM: 49.40 (+0.02), CMP: 89.12 (+0.43), VRSK: 62.78 (-0.34), GILD: 103.93 (-2.97), EXPD: 43.84 (-0.07), TFX: 114.61 (+0.14), CVS: 89.66 (+0.37), PG: 89.41 (-0.07), PX: 126.40 (+0.17), NVS: 94.51 (+1.85)
Malaria No More Reaches Power Of One Campaign Goal for Treatments In Zambia
PR Newswire - Wed Nov 12, 5:54AM CST
Malaria No More announced today that funding has been secured and an order has been placed for three million life-saving malaria treatments in advance of its three year, end of 2015 goal. The Power of One (Po1) campaign uses the latest social, mobile and e-commerce technologies to rally the global public in the fight against malaria. This is a major milestone for the organization and Po1 campaign partners Novartis (NYSE: NVS), the world's leading provider of malaria treatments; and Alere Inc. (NYSE: ALR), the world's leading provider of rapid diagnostic tests for infectious diseases, including malaria. To date, one million rapid diagnostic tests have been sent to Zambia through Po1.
ALR: 39.92 (-0.18), NVS: 94.51 (+1.85)
Global Grass Pollen Allergy Clinical Trials Review, H2 2014: Commercial Landscape of the Major Companies / Universities / Institutes / Hospitals
M2 - Wed Nov 12, 5:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/sjpbh2/grass_pollen) has announced the addition of the "Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Grass Pollen Allergy Global Clinical Trials Review, H2, 2014" provides data on the Grass Pollen Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Grass Pollen Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Grass Pollen Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Grass Pollen Allergy Therapeutics Clinical Trials - ALK-Abello A/S - Stallergenes S.A. - Allergy Therapeutics plc - Laboratorios LETI S.L. - Circassia Holdings Ltd. - Merck KGaA - Merck & Co., Inc. - BioTech Tools s.a. - Novartis AG - Biomay AG Clinical Trial Overview of Top Institutes / Government - University of Zurich - Imperial College London - Johann Wolfgang Goethe University Hospitals - Medical University of Vienna - Charite - Universitatsmedizin Berlin - Azienda Ospedaliera L. Sacco - Nationwide Children's Hospital - Bispebjerg Hospital - University Hospital Freiburg - Rush University Medical Center For more information visit http://www.researchandmarkets.com/research/sj...ass_pollen
MRK: 59.69 (+0.38), NVS: 94.51 (+1.85)
Novartis and Malaria No More help fulfill malaria treatment goal in Zambia by raising funds for three million treatments through Power of One
M2 - Wed Nov 12, 3:18AM CST
o Power of One campaign, supported by exclusive treatment sponsor Novartis, raises funds for three million treatments for children with malaria
NVS: 94.51 (+1.85)
Amgen's brodalumab beats Stelara in Phase 3 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 3:52PM CST
CANF: 2.70 (+0.16), JNJ: 109.04 (+0.29), IDRA: 2.53 (-0.03), DERM: 15.99 (-0.26), MRK: 59.69 (+0.38), PFE: 30.54 (+0.12), AZN: 74.68 (+0.42), AMGN: 160.52 (-1.41), GSK: 45.87 (+0.25), HSP: 57.91 (-0.18), NVS: 94.51 (+1.85), CELG: 107.53 (-0.72)
Product and Pipeline Analysis of the Global Vaccines Market
M2 - Tue Nov 11, 10:32AM CST
Research and Markets (http://www.researchandmarkets.com/research/4nt5s9/product_and) has announced the addition of the "Product and Pipeline Analysis of the Global Vaccines Market " report to their offering. Vaccines represent a class of biologics that are administered to prevent infectious diseases to reduce mortality and morbidity. It is estimated that the introduction of vaccines has reduced the incidence of various diseases by greater than 90%. This study examines the global vaccines market, including marketed products and products under clinical development. It also presents an overview of the value chain and regulatory environment, and offers profiles of key marketed and pipeline products. The market is segmented into infectious disease vaccines, cancer vaccines, allergy vaccines, and others (e.g., vaccines for physiological disorders such as diabetes and Alzheimer's disease). The base year is 2013. Key Findings:Vaccines are a class of biologics administered to prevent infectious diseases and reduce mortality and morbidity. - Vaccines are now available for prevention of about infectious diseases. - Coupled with powerful techniques such as polymerase chain reaction (PCR), mass spectrometry, and next-generation sequencing, the vaccine industry experienced a paradigm shift resulting in innovation and engineering of novel vaccines such as dendritic cell, DNA, and synthetic. - Infectious disease vaccines-particularly viral vaccines-represent the largest share in terms of products under clinical trial. There is an increased focus on developing vaccines with alternative delivery routes, such as oral and intranasal, to effectively replace the conventional injection method of administration. - One of the hallmarks of vaccine development is the improved understanding of the immune system. As a result, developers are pursuing vaccines for physiological diseases. - Developers also are researching vaccines for emerging infectious diseases such as respiratory syncytial virus (RSV), norovirus, human immunodeficiency virus (HIV), Epstein-Barr, malaria, and Leishmaniasis. - The United States, Europe, and Japan represent the largest markets for vaccine manufacturers; however, with increasing healthcare spending and awareness, emerging regions represent the fastest-growing and attractive markets. Key Topics Covered: 1. Executive Summary 2. Methodology and Scope 3. Introduction 4. Global Regulatory Oversight 5. Competitive Landscape 6. Competitive Landscape-Bacterial Vaccines 7. Competitive Landscape-Viral Vaccines 8. Competitive Landscape-Parasitic Vaccines 9. Competitive Landscape-Cancer Vaccines 10. Competitive Landscape-Allergy Vaccines 11. Competitive Landscape-Other Vaccines 12. Bacterial Vaccine Product Dashboard 13. Viral Vaccine Product Dashboard 14. Parasitic Vaccine Product Dashboard 15. Cancer Vaccine Product Dashboard 16. Allergy Vaccine Product Dashboard 17. Other Vaccine Products Dashboard 18. Timeline of Key Events 19. Conclusions Companies Mentioned - AFFiRiS - Archivel Farma - Biondvax - Bionor Pharma - Dendreon - GSK - Greer Laboratories - Immunitor - Inovio - Merck & Co - Nabi - Northwest Biotherapeutics - Novartis - PaxVax - Pfizer - Sanofi - Vaccinogen For more information visit http://www.researchandmarkets.com/research/4n...roduct_and
NWBO: 6.01 (+0.13), MRK: 59.69 (+0.38), NVS: 94.51 (+1.85)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 114.34 (-2.34), GILD: 103.90 (-3.00), MRK: 59.69 (+0.38), DNDN: 0.15 (-0.01), AZN: 74.68 (+0.42), TEVA: 57.80 (-0.64), ABBV: 64.05 (+0.29), GSK: 45.87 (+0.25), BMY: 57.98 (-0.63), NVS: 94.51 (+1.85)
Pharma Equities Technical Data - Salix Pharma, AstraZeneca, Novartis, Impax Laboratories, and Novo Nordisk
PR Newswire - Tue Nov 11, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), AstraZeneca PLC (NYSE: AZN), Novartis AG (NYSE: NVS), Impax Laboratories Inc. (NASDAQ: IPXL), and Novo Nordisk A/S (NYSE: NVO). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 10, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,613.74, up 0.23% and the NASDAQ Composite closed at 4,651.62, up 0.41%. The S&P 500 finished the session 0.31% higher at 2,038.26. During the trading session, eight out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 783.00, up 1.00%, with the index gaining 11.86% in the previous three months. Register for your complimentary reports on these five stocks at:
IPXL: 29.41 (+0.02), NVO: 44.08 (-0.24), AZN: 74.68 (+0.42), SLXP: 96.40 (+0.85), NVS: 94.51 (+1.85)
Sanofi/Regeneron asthma drug successful in Phase 2 trial
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 6:44AM CST
MRK: 59.69 (+0.38), AZN: 74.68 (+0.42), AMGN: 160.52 (-1.41), TEVA: 57.80 (-0.64), THRX: 13.33 (+0.01), GSK: 45.87 (+0.25), SNY: 46.78 (+0.22), REGN: 397.52 (-3.59), NVS: 94.51 (+1.85)
Global Papillary Thyroid Cancer therapeutics Pipeline Report H2 2014 - Analysis of 6 Companies & 8 Drug Profiles
M2 - Tue Nov 11, 3:34AM CST
Research and Markets (http://www.researchandmarkets.com/research/lcrf6q/papillary_thyroid) has announced the addition of the "Papillary Thyroid Cancer - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Papillary Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Papillary Thyroid Cancer and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AstraZeneca PLC - GlaxoSmithKline plc - Plexxikon Inc. - Novartis AG - Exelixis, Inc. - Deciphera Pharmaceuticals, LLC Drug Profiles - vandetanib - everolimus - cabozantinib s-malate - dabrafenib mesylate - rebastinib tosylate - PLX-7486 - CLM-3 - CLM-29 For more information visit http://www.researchandmarkets.com/research/lc...ry_thyroid
AZN: 74.68 (+0.42), GSK: 45.87 (+0.25), NVS: 94.51 (+1.85), EXEL: 1.81 (unch)
WomenHeart Launches First National Patient Education Campaign For Heart Failure In Women
PR Newswire - Mon Nov 10, 4:41PM CST
WomenHeart: The National Coalition for Women with Heart Disease announces the launch of the first national patient education campaign to raise awareness about women and heart failure. Heart failure is the leading cause of hospitalizations in women over the age of 65, and women account for 50 percent of all heart failure-related hospital admissions²; yet, only 25 percent of women are involved in heart failure studies³. The new campaign, which is supported by grants from St. Jude Medical Foundation and Novartis Pharmaceuticals Corporation, and sponsored by Amgen, aims to raise public awareness about women and heart failure, educate and support women with or at risk for heart failure, and develop recommendations for gender-specific heart failure research.
STJ: 65.90 (+0.22), NVS: 94.51 (+1.85)
UCB to Sell Generics Business, Focus on Core Segments - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 4:30PM CST
UCB SA (UCBJF) entered into an agreement with Advent International and Avista Capital Partners for the sale of its specialty generics subsidiary for $1.525 billion.
LCI: 49.67 (-0.06), LLY: 67.94 (+0.54), GSK: 45.87 (+0.25), NVS: 94.51 (+1.85)
Tribute Pharmaceuticals Reports Double Digit Revenue Growth in Third Quarter 2014
Marketwire Canada - Mon Nov 10, 1:03PM CST
Tribute Pharmaceuticals Canada Inc. (OTCQX:TBUFF) (TSX VENTURE:TRX) ("Tribute" or the "Company"
, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the US, today announced financial results for its third quarter ending September 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP). TRX.VN: 0.550 (-0.020), NVS: 94.51 (+1.85)
Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020
M2 - Mon Nov 10, 10:53AM CST
Research and Markets (http://www.researchandmarkets.com/research/r5npxt/nonhodgkin) has announced the addition of the "Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020" report to their offering. The approval of Rituxan (rituximab) has caused the size of the Non-Hodgkin Lymphoma (NHL) market to increase dramatically over the last two decades. This growth is expected to continue at a moderate pace during the forecast period, from $5.6 billion in 2013 culminating in revenues of $9.2 billion by 2020, at a Compound Annual Growth Rate (CAGR) of 7.4%, in the major developed markets. In 2013, the major share of the global NHL market was attributed to by the US, representing 53% of the overall NHL market and this dominance is expected to be retained throughout the forecast period. The increasing uptake of new targeted therapies, especially novel small molecule inhibitors in the relapsed and refractory setting, along with the dominant usage of Rituxan is expected to fuel market growth in all the major developed markets. The expected launches of premium-priced novel antibodies and small molecule inhibitors, especially protein kinase inhibitors, targeting both indolent and aggressive sub-types of NHLs will widen the treatment population eligible for novel targeted and immunotherapies. The anticipated approval of promising pipeline drug candidates, Roche's obinutuzumab, Novartis' Afinitor (everolimus), Takeda's alisertib and Biovest's BiovaxID (dasiprotimut T) and GlaxoSmithKline's Arzerra (ofatumumab) for various NHL subtypes is a key driver for the steady increase in NHL market size. Despite of a flurry of expected launches, the growth in market is not anticipated to grow rapidly, particularly due to loss of patent exclusivity of Rituxan during the forecast period. Recently Launched Targeted and Immunotherapies has Widened Treatment Alternatives for Specific Sub-types Over the past two decades, significant progress has been made in the development of new therapies for NHL. Perhaps the most important milestone is the addition of Rituxan, approved by the US Food and Drug Administration (FDA) for relapsed or refractory Cluster of Differentiation (CD) 20-positive B-cell lymphoma in 1997. Following the approval of Rituxan in 1997, the US FDA approved five other monoclonal Antibodies (mAbs): Campath (alemtuzumab) in 2001, Bexxar (tositumomab) in 2003, Zevalin (ibritumomab tiuxetan) in 2002, Arzerra in 2009, and Adcetris (brentuximab vedotin) in 2011. Another novel mAb, mogamulizumab, which is still in Phase III clinical trials in the US, has already gained approval in Japan. The majority of these drugs are approved for the treatment of specific NHL sub-types. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Marketed Products 4 Pipeline Products 5 Market Forecast to 2020 6 Deals and Strategic Consolidations 7 Appendix For more information visit http://www.researchandmarkets.com/research/r5npxt/nonhodgkin
NVS: 94.51 (+1.85)
(0)
(0)Novartis Ag (NVS) Stock Research Links
Scroll down for more posts ▼